Jun 24, 2026
The Trump administration has launched an investigation into Germany’s pharmaceutical pricing, claiming that “persistent underpayment” for drugs is forcing Americans to subsidize research and development (R & D) globally. And it’s threatening to impose tariffs if those pricing practices are deemed unfair.
In most developed countries, drug prices are set or negotiated by the government. In the U.S., pharmaceutical companies set the prices, based more on what the private market can bear.
Advertisement
That’s created a situation where unbranded generic drugs (about 90% of prescriptions in the U.S.) cost on average 2.78 times higher in this country than in 33 other OECD nations, according to a 2024 RAND report. For brand-name drugs, that gap is even higher, at 4.22 times what other nations pay.
Thanks for subscribing!
Read the best of Moneywise in 5 minutes or less.
By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.
Now, the U.S. wants Germany to follow in the footsteps of the U.K., which recently struck a deal that — in exchange for tariff exemptions — will see the country pay more for new drugs.
But America’s “most favored nation” policy framework “incorrectly deflects blame for high American prices to other countries,” according to the Center for Global Development (CGD).
Government purchasers in the US could use the power of monopsony (being a single buyer) to lower prices for current drugs, and could set up incentives to keep future drugs affordable too, CGD writes, adding the country could “look at ways to rein in pharmaceutical company marketing and patent evergreening strategies.”
Here’s why the issue is so complicated, and what you can do to lower your bill — despite the larger political issues at play.
What’s happening in Europe
In April, the U.K. government agreed to a deal with the U.S. that would see that country increase spending on drugs to avoid U.S. tariffs.
It hasn’t exactly gone over well with the public. This “geopolitical game” risks “sabotaging our carefully worked-out mechanism for keeping a lid on big pharma’s overinflated prices, and they have done so without so much as a debate in parliament,” Nick Dearden, director of Global Justice Now, told The Guardian.
Global pharmaceutical companies, for their part, are threatening to pull investment to pressure policymakers in Europe. And Germany is next on the list.
Pfizer, AstraZeneca and Eli Lilly have all warned Germany that they may not launch new medicines in Germany — or might scrap investment — if Germany’s proposed healthcare changes go ahead.
Advertisement
Thanks to a 20-billion-euro public healthcare budget shortfall, Berlin is proposing reforms such as higher discounts and rebates on pricey new drugs. This is what Washington is taking issue with. But German Chancellor Friedrich Merz says the U.S. must respect Germany’s pharma pricing as a domestic matter.
Must Read
- The ultra-rich use these 5 real estate strategies to build wealth while they sleep — you can start with just $100
- Here’s the average income of Americans by age in 2026. Are you keeping up or falling behind?
- Insurance companies profit most from drivers who auto-renew without shopping around. Comparing 100+ quotes takes 2 minutes and costs nothing
Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
What’s happening in the US
In other OECD countries, governments are the biggest purchasers of any given drug. They negotiate directly with drug companies on behalf of their citizens. According to the Trump administration, “Inflated prices in the United States fuel global innovation while foreign health systems get a free ride.”
But the U.S. has a fundamentally different system than the rest of the world. It has chosen not to have a single public healthcare system that can negotiate drug prices for everyone.
“Other countries are not receiving ‘discounts’ against the US ‘real’ price. Instead, everyone is paying prices somewhere below their willingness to pay (the value of the drug to the purchaser) and somewhere above the marginal cost of producing the drug (the minimum price it is worth selling at for the producer),” the CGD writes.
If the price is too high, “they frequently just wouldn’t buy the drugs.”
Advertisement
So, while the U.S. does, in fact, pay much more for prescription drugs — and those high prices do help fund R & D — the pharmaceutical sector “has systematically fought efforts to negotiate or lower prices for Americans,” according to CGD.
And, despite Washington’s recent deals with pharmaceutical companies to bring down costs, those companies have announced price increases on at least 350 branded drugs for 2026 by a median of 4%, according to healthcare research firm 3 Axis Advisors.
“The United States has deliberately chosen a system permitting manufacturer pricing autonomy, protected by patent laws and regulatory exclusivity provisions, subject to relatively weak constraints from government negotiation and market competition,” notes the nonpartisan educational site GovFacts.
About a quarter of revenues from drug companies are reinvested into R & D, according to estimates by the Congressional Budget Office. The rest goes toward other expenditures, including marketing, lobbying and shareholder profit.
How to keep medication costs under control
With high drug prices, some Americans end up rationing their meds, skipping doses or simply not taking them. And that can lead to worse health outcomes and higher healthcare costs over the long-term.
So how can you reduce your out-of-pocket costs without compromising your health?
Advertisement
Generic medications typically cost less than branded ones, so you can ask your healthcare provider if you can switch to unbranded medications that will treat the same condition.
You can also use price comparison tools (such as GoodRx and Pharmacy Rx) to search prices at different pharmacies. Prices can vary widely for the same medicine (and can change, just like the price of gas), since pharmacies set their own prices.
For Medicare beneficiaries, once you reach your Part D out-of-pocket cap ($2,100 in 2026), you don’t have to pay for the rest of the year — at least for covered meds. You could also be eligible for lower co-payments through the Extra Help program, based on your income.
Some drug companies have patient assistance programs, which could include co-pay assistance and co-pay cards, which provide rebates when you purchase their drugs. Some charities and nonprofits also offer patient assistance or grant programs.
You could also check if your employer offers a Health Care Savings Account (HSA) or Flexible Spending Account (FSA). This can help you save money (and earn interest) specifically for healthcare expenses — and these accounts can be transferred to a new employer.
You May Also Like
- JP Morgan sees gold hitting $6,000/oz before 2027 — and a Gold IRA lets you hold the physical metal while deferring the tax bill. Get your free guide from Priority Gold
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here’s what it is and the simple steps to fix it ASAP
- Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
- Millionaires under 43 are reshaping investing — just 25% of their portfolios are in stocks. Here’s where their money is going
Vawn Himmelsbach is a veteran journalist who covers tech, business, finance and travel. Her work has been featured in publications such as The Globe and Mail, Toronto Star, National Post, CBC News, Yahoo Finance, MSN, CAA Magazine, Travelweek, Explore Magazine and Consumer Reports.
